AP NEWS

Personalis, Inc. to Present at the 3rd Annual NeoAG Summit Boston

November 14, 2018

MENLO PARK, Calif.--(BUSINESS WIRE)--Nov 14, 2018--Personalis, Inc., a leader in advanced genomics for precision oncology, today announced that they are scheduled to present at the upcoming NeoAG Summit in Boston, MA on Thursday, November 15, 2018 at 4 PM ET.

The presentation, entitled “ImmunoID NeXT Platform: Improving Neoantigen Prediction, TME Assessment, and ctDNA Detection for Vaccine Development,” will introduce Personalis’ new ImmunoID NeXT Platform and discuss how it facilitates highly accurate neoantigen identification, optimal MHC-binding prediction and ranking, and the assessment of the tumor microenvironment and tumor escape mechanisms that may impact response to personalized therapeutics.

ImmunoID NeXT is the first and only platform to provide comprehensive analysis of both a tumor and its microenvironment from a single sample. The platform can be used to investigate the key tumor- and immune-related areas of cancer biology; consolidating multiple oncology biomarker assays into one. This maximizes the biological information that can be generated from a precious tumor specimen.

The presentation will be delivered by Sean Boyle, PhD; Director, Bioinformatics Applications.

About Personalis, Inc.

Personalis, Inc. is a leader in advanced genomics for precision oncology translational research and clinical trials, dedicated to enabling the development of the next generation of oncology therapeutics. The company’s ImmunoID NeXT Platform comprehensively characterizes the tumor and the tumor microenvironment, facilitating the analysis of key predictive and investigational oncology biomarkers from a single sample. The Personalis  Clinical Laboratory is GxP aligned as well as CLIA’88-certified and CAP-accredited. For more information, please visit  www.personalis.com and follow Personalis on Twitter ( @PersonalisInc ).

View source version on businesswire.com:https://www.businesswire.com/news/home/20181114005321/en/

CONTACT: Personalis, Inc.

Jennifer Havlek, 650-752-1300

pr@personalis.com

www.personalis.com

KEYWORD: UNITED STATES NORTH AMERICA CALIFORNIA MASSACHUSETTS

INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY CLINICAL TRIALS GENETICS ONCOLOGY PHARMACEUTICAL RESEARCH SCIENCE

SOURCE: Personalis, Inc.

Copyright Business Wire 2018.

PUB: 11/14/2018 11:00 AM/DISC: 11/14/2018 11:00 AM

http://www.businesswire.com/news/home/20181114005321/en

AP RADIO
Update hourly